Trex Wind-down, Inc. (BPC.F)
Trex Wind-down, Inc.
3 Mountain View Road
Suite 100
Warren, NJ 07059
United States
973 314 9577
https://www.timberpharma.com
Sector(s):
Industry:
Full Time Employees: 9
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John Koconis M.B.A. | Chairman, CEO & President | 530.04k | N/A | 1971 |
| Mr. Joseph Lucchese | Executive VP, CFO, Treasurer & Secretary | 504.11k | N/A | 1968 |
| Dr. Alan Mendelsohn M.D. | Executive VP & Chief Medical Officer | 471.44k | N/A | 1964 |
Description
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Corporate Governance
Trex Wind-down, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
